Enzymatica AB (publ) (STO:ENZY)
Sweden
· Delayed Price · Currency is SEK 3.480
+0.320 (10.13%)
May 13, 2025, 5:11 PM CET
Enzymatica AB Revenue
Enzymatica AB had revenue of 12.28M SEK in the quarter ending March 31, 2025, with 30.33% growth. This brings the company's revenue in the last twelve months to 48.43M, up 2.42% year-over-year. In the year 2024, Enzymatica AB had annual revenue of 45.58M, down -10.47%.
Revenue (ttm)
48.43M
Revenue Growth
+2.42%
P/S Ratio
15.84
Revenue / Employee
2.31M
Employees
21
Market Cap
767.04M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 45.58M | -5.33M | -10.47% |
| Dec 31, 2023 | 50.90M | 1.96M | 4.00% |
| Dec 31, 2022 | 48.95M | -8.30M | -14.49% |
| Dec 31, 2021 | 57.24M | -54.00M | -48.54% |
| Dec 31, 2020 | 111.25M | 49.94M | 81.46% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Swedish Orphan Biovitrum AB | 26.24B |
| Sectra AB | 3.30B |
| Getinge AB | 35.57B |
| Camurus AB | 1.87B |
| Medicover AB | 23.56B |
| AddLife AB | 10.42B |
| Vitrolife AB | 3.61B |
| Vimian Group AB | 4.24B |